Get the Stockscreener App
31.16
0.74%
0.23
After Hours:
30.93
-0.23
-0.74%
Smith Nephew Plc Adr stock is traded at $31.16, with a volume of 1.39M.
It is up +0.74% in the last 24 hours and down -2.90% over the past month.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
See More
Previous Close:
$30.93
Open:
$31.05
24h Volume:
1.39M
Relative Volume:
1.52
Market Cap:
$13.30B
Revenue:
$6.18B
Net Income/Loss:
$626.40M
P/E Ratio:
21.71
EPS:
1.435
Net Cash Flow:
$848.81M
1W Performance:
-1.30%
1M Performance:
-2.90%
6M Performance:
-15.37%
1Y Performance:
+10.42%
1-Day Range:
$31.00
$31.45
1-Week Range:
$30.36
$32.27
52-Week Range:
$27.97
$38.79
Smith Nephew Plc Adr Stock (SNN) Company Profile
Compare SNN vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNN
Smith Nephew Plc Adr
|
31.16 | 13.26B | 6.18B | 626.40M | 848.81M | 1.435 |
ABT
Abbott Laboratories
|
89.46 | 163.10B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
294.73 | 123.10B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
80.00 | 105.15B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
56.50 | 86.87B | 20.62B | 3.56B | 3.66B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.98 | 47.44B | 6.30B | 1.07B | 1.34B | 1.8406 |
Smith Nephew Plc Adr Stock (SNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-14-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-25-25 | Downgrade | HSBC Securities | Buy → Hold |
| Mar-12-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-24 | Downgrade | Berenberg | Buy → Hold |
| Nov-01-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-24 | Initiated | Deutsche Bank | Buy |
| Jun-05-24 | Upgrade | UBS | Neutral → Buy |
| Nov-28-23 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-03-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-31-23 | Upgrade | HSBC Securities | Hold → Buy |
| Oct-13-23 | Initiated | Stifel | Hold |
| Aug-08-23 | Upgrade | UBS | Sell → Neutral |
| Apr-27-23 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-12-22 | Initiated | Citigroup | Buy |
| Nov-28-22 | Downgrade | UBS | Neutral → Sell |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-28-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-15-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-22 | Upgrade | Redburn | Sell → Neutral |
| Jun-09-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-18-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-01-20 | Initiated | Barclays | Overweight |
| Jul-29-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-21-19 | Initiated | Citigroup | Buy |
| Nov-12-19 | Initiated | Bernstein | Outperform |
| Jul-23-19 | Upgrade | Berenberg | Hold → Buy |
| Feb-08-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Jan-02-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-01-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-25-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-11-17 | Initiated | Canaccord Genuity | Buy |
| Feb-27-17 | Downgrade | Goldman | Buy → Neutral |
| Jan-19-17 | Initiated | HSBC Securities | Hold |
| Dec-08-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-06-16 | Downgrade | Berenberg | Buy → Hold |
| Feb-26-16 | Initiated | Cantor Fitzgerald | Hold |
View All
Smith Nephew Plc Adr Stock (SNN) Latest News
Wound Cleanser Products Market Size is Projected to be USD 5.17 Billion by 2035; Industry is Propelling Owing to the Growing Technological Investments Globally - GlobeNewswire Inc.
Smith+Nephew’s REGENETEN◊ Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,* - Sahm
New data for Smith+Nephew’s CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant demonstrates superior pain relief and functional gains at 5-years - ChartMill
Smith & Nephew plc (ADR) stock (US83175M2052): Why Google Discover changes matter more now for medte - AD HOC NEWS
Smith & Nephew plc (ADR) stock (US83175M2052): Why its medtech innovation edge is suddenly worth a c - AD HOC NEWS
Smith & Nephew PLC (NYSE:SNN) Passes the Caviar Cruise Screen for Quality Investing - ChartMill
Smith & Nephew plc (ADR) Stock: Global Medtech Leader Faces Evolving Orthopedics and Sports Medicine - AD HOC NEWS
Smith & Nephew plc (ADR) stock faces pressure amid regulatory hurdles and slowing ortho demand - AD HOC NEWS
Smith & Nephew plc (ADR) Stock (ISIN: US83175M2052) Faces Headwinds Amid Medtech Sector Slowdown - AD HOC NEWS
Smith+Nephew launches next-generation ALLEVYN COMPLETE CARE Foam Dressingdesigned for high performance in wound management and pressure injury prevention - Finviz
Smith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressingdesigned for high performance in wound management and pressure injury prevention - ChartMill
NVIDIA Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026 - Sahm
Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026 - ChartMill
Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026 - Finviz
Smith & Nephew FTSE Healthcare Market Presence and Operational Developments - Kalkine Media
Smith+Nephew signs exclusive US distribution agreement with RMR Ortho for patented technology that provides a unique dynamic compression nitinol fixation option (A'TOMIC) to our surgeons - Finviz
Smith+Nephew signs exclusive US distribution agreement with RMR Ortho for patented technology that provides a unique dynamic compression nitinol fixation option (A'TOMIC™) to our surgeons - Sahm
Smith+Nephew signs distribution agreement with SI-BONE - Finviz
Factory Mutual Insurance Co. Buys New Stake in Smith & Nephew SNATS, Inc. $SNN - Defense World
Smith & Nephew (NYSE: SNN) leaders add ADS via plan - Stock Titan
Jim Cramer on Smith & Nephew: "This Group, I Do Not Like" - Finviz
Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair - Finviz
The Truth About Smith & Nephew plc: Why This ‘Boring’ Med-Tech Stock Might Be Your Sneaky Power - AD HOC NEWS
Smith & Nephew ADR trying to close in on key technical benchmark - MSN
The Truth About Smith & Nephew plc (ADR): Wall Street Sleeper Stock or Total Snooze? - AD HOC NEWS
Smith & Nephew plc (ADR): Quiet Charts, Cautious Optimism – Is SNN a Sleeper in Medtech? - AD HOC NEWS
Smith & Nephew (SN, SNN) Stock Outlook for December 2025: Q3 Setback, $500m Buyback and What Comes Next - ts2.tech
Smith and Nephew (LON:SN) positioned across FTSE 100 Today healthcare landscape - Kalkine Media
FTSE 100 today: Pound lower; Magnum debuts, Smith & Nephew sets new goals - Investing.com
Smith & Nephew Unveils RISE Blueprint for a Stronger Future - Kalkine Media
Smith+Nephew sets ambitious growth targets through 2028 - Investing.com
Smith Nephew Plc Adr Stock (SNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):